The trajectory of Viagra, formerly marketed by copyright, presents a intricate case study for backers considering the healthcare sector. Despite its early success and impact of billions in earnings , the exclusivity lapse has opened the way for alternative medications, substantially eroding income opportunities. This transition raises questions abo